Improving the Efficacy of Abiraterone
James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses how his laboratory is working to improve the efficacy of abiraterone for the treatment of prostate cancer.
Clinical Pearls
James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses how his laboratory is working to improve the efficacy of abiraterone for the treatment of prostate cancer.
- A better understanding of the last 2 steps of the backdoor pathway could lead to improved treatment as androgen synthesis inhibitors (abiraterone, TAK-700, and TOK-001) all work upstream, far from DHT
- Researchers are testing whether an attack next to the preferred androgen DHT will improve response to FDA-approved agents
- Androgen deprivation therapy may be more effective if DHT levels in the tissue are reduced to 0
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
